Aura Biosciences, Inc.

34 articles with Aura Biosciences, Inc.

• 

  BioSpace Movers & Shakers, Jan. 8

  1/8/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Aura Biosciences Appoints David Johnson to Its Board of Directors

  1/5/2021

  Aura Biosciences, a clinical-stage oncology company developing a novel class of drug conjugate therapies for multiple oncology indications, today announced the appointment of David Johnson to its Board of Directors

• Aura Biosciences Announces AU-011 Data From Phase 1b/2 Clinical Trial Selected for Late Breaking Presentation at the Upcoming American Academy of Ophthalmology 2020 Virtual Annual Meeting

  11/10/2020

  Late Breaker to be Presented by Leading Ocular Oncologist, Carol L. Shields, M.D., Director, Ocular Oncology Service, Wills Eye Hospital A Total of Three Abstracts Highlighting AU-011 Selected for Presentation

• Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma

  9/11/2020

  Study Being Led by Leading Ocular Oncologist, Carol L. Shields, M.D., Director, Ocular Oncology Service, Wills Eye Hospital

• Aura Biosciences Presents Updated AU-011 Clinical Data at ARVO 2020

  6/12/2020

  AU-011 Continues to Demonstrate a Favorable Safety Profile Along with Promising Tumor Control and Vision Preservation Same AU-011 Data Will Also be Virtually Presented at the Upcoming World Ophthalmology Congress 2020 and American Society of Retinal Specialists 2020 Annual Meeting

• Aura Biosciences to Present at the Cowen 40th Annual Health Care Conference

  2/25/2020

  Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tumors such as ocular and bladder cancers, today announced that Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura, will present a company overview at the Cowen 40th Annual Health Care Conference

• Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the 43rd Annual Macula Society Meeting

  2/24/2020

  Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tumors such as ocular and bladder cancers, today announced the presentation of updated clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011

• Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors

  1/7/2020

  Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tumors such as ocular and bladder cancers, today announced the appointment of George Golumbeski, Ph.D., as Chairman of its Board of Directors.

• Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at the American Academy of Ophthalmology 2019 Annual Meeting

  10/15/2019

  Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced the presentation of updated clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the first line treatment of primary choroidal melanoma, at the American Academy of Ophthalmology (AAO) 2019 Annual Meeting, being held October 12-15, 2019 in San Francisco, CA.

• Aura Biosciences Announces Clinical Data Presentations at the Upcoming American Academy of Ophthalmology 2019 Annual Meeting

  9/26/2019

  Phase-1b/2 Clinical Data for Aura’s Lead Asset, AU-011, to be Highlighted at the Meeting and at Other Related Events

• Aura Biosciences Announces Participation at Upcoming Investor Conferences

  8/1/2019

  Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, announced that members of Aura’s executive team will participate in the following upcoming investor conferences

• Aura Biosciences to Present Long-Term Clinical Data for AU-011 at the 37th Annual Scientific Meeting of the American Society of Retina Specialists

  7/24/2019

  Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that two-year clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011,

• Clearside Biomedical Announces License Agreement with Aura Biosciences for Suprachoroidal Space Microinjector™ Designed to Optimize Ocular Oncology Drug Delivery

  7/9/2019

  Clearside Biomedical, Inc. announced its entry into a worldwide licensing agreement with Aura Biosciences for the use of Clearside’s Suprachoroidal Space Microinjector™ to deliver Aura’s proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choroidal melanoma.

• Aura Biosciences to Present Interim Phase 1b/2 Clinical Data for AU-011 at the European Society of Ophthalmology 2019 Congress

  6/14/2019

  Aura Biosciences announced that interim clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the treatment of primary choroidal melanoma, will be highlighted in an oral presentation at the European Society of Ophthalmology 2019 Congress being held June 13-16, 2019, in Nice, France.

• Aura Biosciences to Present at the Jefferies 2019 Global Healthcare Conference

  5/28/2019

  Aura Biosciences announced that Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura, will present a company overview at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019, at 2:00 p.m. Eastern Time in New York, NY.

• Aura Biosciences to Present Two Year Phase 1b/2 Clinical Data for AU-011 at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting

  4/22/2019

  Aura Biosciences announced that two year clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the primary treatment of primary choroidal melanoma, will be highlighted in a poster presentation at the Association for Research in Vision and Ophthalmology 2019 Annual Meeting being held April 28-May 2, 2019, in Vancouver, British Columbia.

• Aura Biosciences Completes $40 Million Series D Financing

  4/2/2019

  Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, announced that it closed a $40 million Series D financing.

• Aura Biosciences to Present Interim Phase 1b/2 Clinical Data for AU-011 at the International Society of Ocular Oncology 2019 Annual Meeting

  3/21/2019

  Aura Biosciences announced that interim clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the primary treatment of primary choroidal melanoma, will be highlighted in an oral presentation at the International Society of Ocular Oncology 2019 Annual Meeting being held March 22-26, 2019, in Los Angeles.

• Aura Biosciences to Present at Upcoming Investor Conferences

  3/5/2019

  Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that management will present a company overview at the following investor conferences:

• Aura Biosciences Announces Successful Outcome of End of Phase 2 Meeting with FDA for AU-011 for the Treatment of Patients with Choroidal Melanoma

  1/4/2019

  Agreement with FDA on Clinical Endpoints and Regulatory Path for Approval